Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0014-4894(81)90078-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metabolic changes that allow artemisinin-resistant parasites to tolerate oxidative stress.
Front Parasitol
September 2024
Centro de Cálculo Científico de la Universidad de Los Andes (CeCalCULA), Universidad de Los Andes (ULA), Mérida, Venezuela.
Artemisinin-based treatments (ACTs) are the first therapy currently used to treat malaria produced by . However, in recent years, increasing evidence shows that some strains of are less susceptible to ACT in the Southeast Asian region. A data reanalysis of several omics approaches currently available about parasites of that have some degree of resistance to ACT was carried out.
View Article and Find Full Text PDFUsefulness of polymerase chain reaction tests in Chagas disease studies.
Front Parasitol
February 2024
National Reference Center for Parasitology, Research Institute of the McGill University Center, Montreal, QC, Canada.
The Polymerase Chain Reaction (PCR) test is a highly sensitive, specific, and rapid diagnostic tool for Chagas disease. Chagas disease is caused by the protozoan flagellate and is endemic to the Americas. While conventional serological methods are still used in the diagnosis of Chagas disease, they are being gradually replaced by molecular methods like PCR.
View Article and Find Full Text PDFMolecular analysis of zoonotic pathogens in free-ranging six-banded armadillos (Euphractus sexcinctus) from the Brazilian semiarid region.
Rev Bras Parasitol Vet
January 2025
Hospital Veterinário Jerônimo Dix-Huit Rosado Maia, Universidade Federal Rural do Semi-Árido - UFERSA, Mossoró, RN, Brasil.
This study investigated infection by Leishmania spp., Leptospira spp., Toxoplasma gondii, and Trypanosoma cruzi in six-banded armadillos (Euphractus sexcinctus) from the semiarid region of northeastern Brazil.
View Article and Find Full Text PDFDiscovery of a Potent Triazole-Based Reversible Targeted Covalent Inhibitor of Cruzipain.
ACS Med Chem Lett
January 2025
Sustainable Chemistry for Metals and Molecules, Department of Chemistry, KU Leuven, Leuven 3000, Belgium.
Cruzipain (CZP) is an essential cysteine protease of , the etiological agent of Chagas disease, and a promising druggable target. To date, no CZP inhibitors have reached clinical use, with research efforts mostly hampered by insufficient potency, limited target selectivity or lack of bioactivity translation from the isolated enzyme to the parasite in cellular environments. In this study, we report the design of , a 1,2,3-triazole-based targeted covalent inhibitor with nanomolar potency (IC = 28 nM) and null inhibition of human cathepsin L.
View Article and Find Full Text PDFImpact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis.
EClinicalMedicine
January 2025
Division of Infectious Diseases, Department of Medicine, University of Colorado Denver, Aurora, CO, USA.
Background: Endemic in more than 20 countries, Chagas disease affects 6.3 million people worldwide, leading to 28,000 new infections and 7700 deaths each year. Previous meta-analyses on antiparasitic treatment need updates to encompass recent studies and to assess key clinically meaningful endpoints.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!